Skip to main content

Table 2 Comparison of variables between baseline and 6 months after the administration of dapagliflozin

From: Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure

 Baseline6 monthsp value
Clinical characteristics
 Body mass index, kg/m225.9 ± 5.125.4 ± 5.1< 0.001
 Systolic blood pressure, mmHg130 ± 16128 ± 180.218
 BNP, pg/mL27.9 (9.0–58.2)28.9 (9.6–62.9)0.132
 eGFR, mL/min/1.73 m270.6 ± 17.065.6 ± 15.30.001
 HbA1c, %7.2 ± 0.87.0 ±0.80.108
Echocardiographic parameters
 LV end-diastolic volume, mL74.2 (55.1–104.1)68.5 (54.8–93.8)0.270
 LV end-systolic volume, mL24.7 (17.0–54.5)20.5 (15.2–57.1)0.105
 LVEF, %62.3 (49.3–68.3)63.6 (55.3–71.0)0.011
 LVMI, g/m275.0 (61.7–92.0)67.0 (55.0–81.9)<0.001
 LAVI, mL/m231 (23–45)26 (21–32)0.001
 E/e′9.3 (7.7–11.8)8.5(6.6–10.7)0.020
  1. Data are mean ± SD for normally distributed data and median and interquartile range for non-normally distributed data, or n (%)
  2. Abbreviation as in Table 1